Studies have found that smoking marijuana exposes you to low levels of the same carcinogenic chemicals in tobacco smoke
- Researchers collected blood and urine samples from 245 HIV volunteers
- They used HIV patients due to high levels of marijuana and smoking
- They found evidence of naphthalene, acrylonitrile and acrylamide chemicals
- These may all be carcinogens in humans, and compared with people who smoke, cannabis smoking has lower carcinogen levels
A new study shows that smoking marijuana exposes the human body to some of the same toxic chemicals released by tobacco, but in lower levels.
Scientists at the Dana-Farber Cancer Institute and the Centers for Disease Control and Prevention studied the levels of several dangerous chemicals in the blood and urine of 245 volunteers.
Some volunteers do not smoke, some smoke weed or tobacco, and dome smokes both.
They found that the systems of those who only smoke marijuana still contained several toxic chemicals related to smoking, but their levels were lower than those of those who only smoked or only smoked.
The researchers said these compounds include naphthalene, acrylonitrile and acrylamide. These toxic chemicals can cause liver damage and are related to cancer and a range of other health problems.
However, another chemical, acrolein, is known to cause cardiovascular disease in smokers-only increased in smoking and not in marijuana.
The research team said that reducing smoking and other sources of acrolein exposure may be a strategy to reduce the risk of cardiovascular disease.

Those who only smoke marijuana still have several toxic chemicals related to smoking in their systems, but their levels are lower than those who only smoke marijuana.
In the United States, the use of marijuana is on the rise, and more and more states legalize it for medical and non-medical purposes-including five other states in the 2020 election.
Dana-Farber’s senior author Dana Gabuzda, MD, said: “This increase has renewed concerns about the potential health effects of cannabis smoke, which is known to be the same as certain toxic combustion products in tobacco smoke.”
“This is the first study to compare the exposure of proprietary cannabis smokers and smokers to acrolein and other harmful smoke-related chemicals over time, and to see if these exposures are related to cardiovascular disease.”
The study involved 245 HIV-positive and HIV-negative participants in three HIV infection studies in the United States. People living with HIV are used because of the high rates of tobacco and marijuana smoking in this group.
The researchers collected data from the participants’ medical records and survey results, and analyzed the breakdown of nicotine or the burning of tobacco or marijuana in their blood and urine samples.
Combining these data sets, they can track the presence of specific toxic chemicals in tobacco or marijuana smoking.
They can also see if it is related to an increased risk of heart disease.
Acrylamide is a chemical found in tobacco and hemp smoke, used to make paper, plastics, and dyes, and is produced when vegetables are heated to high temperatures.
The chemical is considered “possibly human carcinogen” by the National Toxicology Program and the American Cancer Society.

The research team said that reducing smoking and other sources of acrolein exposure may be a strategy to reduce the risk of cardiovascular disease.Stock Images
At the same time, acrylonitrile, found as a by-product of smoking weed and tobacco, is used to make plastics and fibers.
The World Health Organization says that cigarette smoke may be an important source of acrylonitrile in indoor air pollution and is considered a possible carcinogen.
Researchers also suggest that high acrolein levels in smokers may be a sign of increased risk of cardiovascular disease, and reducing exposure to the chemical can reduce the risk.
Given the high smoking rate and the increased risk of heart disease in this population, this is very important for people infected with HIV (the virus that causes AIDS).
Gabuzda said that our findings indicate that high acrolein levels can be used to identify patients with increased cardiovascular risk, and reducing exposure to acrolein from smoking and other sources may be a strategy to reduce risk.
The discovery has been published in “EClinical Medicine” magazine.